| 包装 | 价格(元) |
| 10mg | 电议 |
| 50mg | 电议 |
Cell lines | MEF cells |
Preparation method | Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 10 μM, 20 μM, 30 μM and 40 μM |
Applications | Co-incubation of BAM7 (10 μM, 20 μM, 30 μM and 40 μM) and monomeric BAX (5 μM) induced dose- and time-responsive BAX oligomerization. BAM7 selectively impaired the viability of Bak-/- MEFs but had no effect on MEFs that lack BAX (Bax-/-) or both BAX and BAK (Bax-/- Bak-/-). BAM7 dose-dependently impaired the viability of BAX-reconstituted, but not BAXK21E-reconstituted, Bax-/- Bak-/- MEFs. Bak-/- MEFs demonstrated the morphologic features of apoptosis in response to BAM7 treatment (15 μM). |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | BAM7 is a direct and selective activator of BAX with IC50 value of 3.3uM [1]. In the competitive fluorescence polarization assay (FPA), BAM7 competes with FITC–BIM SAHB for BAX binding site(BH3) in a dose dependent manner. BAM7 shows no antiapoptotic or BAKΔC competitive binding interactions even at 50 μM dosing, revealing a remarkable selectivity of BAM7 for BAX. The interaction between BAM7 and BAX at the very surface induces the characteristic structural changes that yield functional BAX oligomerization. In the in vitro assay, BAM7 induces BAX-dependent cell death but not the cells with BAK. BAM7 could be developed to a new generation of apoptotic modulators that directly activate BCL-2 family executioner proteins in cancer and other diseases driven by pathologic apoptotic blockades [1]. References: |
m.cnreagent.com